about
Costs of occupational injuries in agricultureHepatitis C virus infection in san francisco’s HIV-infected urban poorCost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C.Economic burden of hepatitis C-associated diseases in the United States.Health care costs associated with hepatitis C: a longitudinal cohort studyCurrent and future disease progression of the chronic HCV population in the United States."Test, Listen, Cure" (TLC) Hepatitis C Community Awareness Campaign.Hepatitis infection in the treatment of opioid dependence and abuse.Labour productivity losses caused by premature death associated with hepatitis C in Spain.Prospects for dendritic cell vaccination in persistent infection with hepatitis C virusClinical outcomes of hepatitis C treated with pegylated interferon and ribavirin via telemedicine consultation in Northern CaliforniaEpoetin alfa for the treatment of combination therapy-induced hemolytic anemia in patients infected with hepatitis C virus.Assessing evidence from clinical trials in chronic hepatitis C.Funding of research on headache disorders by the National Institutes of HealthAssociation of hepatitis C virus infection with prevalence and development of kidney disease.Global control of hepatitis C: where challenge meets opportunityDirect medical care costs associated with patients diagnosed with chronic HCV.Capacity enhancement of hepatitis C virus treatment through integrated, community-based care.Patterns of Healthcare Utilization Among Veterans Infected With Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) and Coinfected With HIV/HCV: Unique Burdens of Disease.Review of cost-effectiveness studies of pegylated therapies for hepatitis C.Emerging therapies for hepatitis C virus.Non-healthcare costs of hepatitis C: A systematic review.Management of Cirrhotic Patients After Successful HCV Eradication.Knowledge about infection is the only predictor of treatment in patients with chronic hepatitis C.The Impact of Redistricting Proposals on Health Care Expenditures for Liver Transplant Candidates and Recipients.Future trends of HCV-related cirrhosis and hepatocellular carcinoma under the currently available treatments.Hepatitis C: What lies ahead and can we afford it?The spectrum of chronic hepatitis C virus infection in the Virginia Correctional System: development of a strategy for the evaluation and treatment of inmates with HCV.Serum lipids and their associations with viral levels and liver disease severity in a treatment-naïve chronic hepatitis C type 1-infected cohort.Direct medical care costs among pegylated interferon plus ribavirin-treated and untreated chronic hepatitis C patients.Economic model of a birth cohort screening program for hepatitis C virus.Assessment of the relative dose-response test as indicators of hepatic vitamin A stores in various stages of chronic liver disease.Depression, anxiety, post-traumatic stress, and alcohol-related problems among veterans with chronic hepatitis C.Assessing variation in the costs of care among patients awaiting liver transplantation.AIDS Drug Assistance Programs: highlighting inequities in human immunodeficiency virus-infection health care in the United States.Vitamin A deficiency in patients with hepatitis C virus-related chronic liver disease.Prevalence and economic burden of extrahepatic manifestations of hepatitis C virus are underestimated but can be improved with therapy.[Kidney and liver support therapies: state-of-the-art methods].Hepatitis C in Lebanon: the burden of the disease and the value of comprehensive screening and treatment
P2860
Q25017353-193654A7-E0B5-4298-B11B-CB22655186D9Q27473306-94A4F7AE-ACB3-48FD-89D3-E061896C6CA6Q30444892-5A7FAE38-56E5-4D4E-9E1E-0320610B44CDQ34253963-909C7751-C2AD-4007-938F-311CE7E41368Q34417139-05B24766-D4BB-4FA9-B849-7658F623B3B7Q34737843-4824DC1B-62F2-4246-A4CC-0051B5035F3EQ35127108-03BED182-1C3B-420C-B2C0-EB9AB310AAE1Q35389163-D8852E39-341E-4845-92E5-39528C132A5AQ35558268-08E0882E-FFDD-486E-97CF-BC37CB819703Q35784239-7C9B1BF8-63EA-4816-BD29-5BD50DA4DF04Q36112998-C1DEC2AF-EDA4-4A94-AA06-FFC58517ACD5Q36146443-BCE1B59D-826B-4826-9885-BA105AF307BCQ36455982-9FDE3FD7-A663-419A-9497-EC406217BB97Q36513964-C75EE262-B6B5-4E2A-95F5-1631251E7C65Q36782599-8C5656F8-C50C-49BE-921E-FA6F6727659BQ37077112-747BABEB-45E3-4291-A39D-0E9785C95A4AQ37078173-6AA16295-5969-4FF3-B93D-F8DCA9D14A41Q37136533-690505C0-9D62-4388-9802-682214E4E7EAQ37305565-928EDE0C-5F70-4B79-BF3B-0EFAA5A54395Q37609421-0AE2C0F4-D1CC-4254-BDAC-4D2219A7AF2EQ37772514-A10CCE48-8EE6-4D2A-BCA6-12282F64A4DEQ38606907-FC224D95-CFB6-45C4-94C1-D735A984034FQ39260393-4292D712-8C16-402B-9456-784749EC85C1Q39394760-EE94D89D-84E5-439F-8779-1E337221827CQ40095028-5F83BA8E-D812-4CA3-B323-F63833DDFF7BQ40396191-460D6AE3-78F7-4E6F-875B-28C4BF2344ECQ40484162-36228946-2DC4-4D18-A440-CCEAE9224933Q42990208-0961EFD3-8C26-41D3-BD5F-A1C7418A182AQ43001446-1CD9E469-36BF-4175-A073-3841959F1B21Q43038208-5674AE3E-138F-48C7-B2F9-64D180412E68Q43047944-5AAC53C7-D7F8-46E8-A958-0ED6B10E02B8Q43613684-9FCE713F-38CD-490C-8BBB-08B8B706EFD0Q44183496-C2A4322F-9570-40BC-A7C3-19C99396F140Q44814074-A3859F72-8CFC-401C-BE75-3B233C40B478Q45203047-386BD7C0-26B7-45B5-82AE-CC82C67A2ED5Q45365149-90E26818-4620-4323-BE20-36972421C45DQ51366504-A556C396-22E8-4DF2-8FDD-0FB8153BF0F4Q51925020-872EA009-5F27-495A-BC31-4CEBB84FE9EDQ57167190-880CFA80-9E5E-4F46-864A-DBFED26FF75F
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Costs of hepatitis C
@ast
Costs of hepatitis C
@en
Costs of hepatitis C
@en-gb
type
label
Costs of hepatitis C
@ast
Costs of hepatitis C
@en
Costs of hepatitis C
@en-gb
prefLabel
Costs of hepatitis C
@ast
Costs of hepatitis C
@en
Costs of hepatitis C
@en-gb
P2093
P921
P3181
P1476
Costs of hepatitis C
@en
P2093
Bruce N. Leistikow
Christopher L. Bowlus
J. Paul Leigh
P2880
P3181
P356
10.1001/ARCHINTE.161.18.2231
P407
P577
2001-10-08T00:00:00Z